Literature DB >> 18785891

Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype.

Y-C Chen, C-Y Chu, C-H Hsiao.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785891     DOI: 10.1111/j.1468-3083.2008.02988.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  6 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

2.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

Review 3.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

4.  Genetic predisposition to oxcarbazepine induced Stevens-Johnson syndrome.

Authors:  Pranay Wal; Ankita Wal; Umeshwar Pandey; Awani K Rai; Anil Bhandari
Journal:  Indian J Crit Care Med       Date:  2011-07

5.  The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population.

Authors:  Yu-Dan Lv; Fu-Li Min; Wei-Ping Liao; Na He; Tao Zeng; Di-Hui Ma; Yi-Wu Shi
Journal:  BMC Neurol       Date:  2013-07-08       Impact factor: 2.474

6.  Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription.

Authors:  Suraya Ahmad Nasir; Huann Lan Tan; Hui Jan Tan; Haizal Mohd Hussaini; Roszalina Ramli
Journal:  Case Rep Dent       Date:  2017-04-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.